Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Pfizer

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: PF-00299804

Study type: Interventional

Funder types: Industry

Identifiers

NCT00225121

A7471001

2005-001140-23 (EudraCT Number)

Details and patient eligibility

About

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Enrollment: 121 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Malignant solid tumor for which there is no currently approved treatment
• Adequate bone marrow, liver, cardiac, and kidney function

Exclusion criteria

• Cardiac disease
• Anticancer therapy within 4-6 weeks (depending on therapy)
• Pregnant or breast-feeding

Trial design

121 participants in 1 patient group

1

Experimental group

Description:

open label single arm trial

Treatment:

Drug: PF-00299804